Insider Transactions in Q1 2025 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2025
|
Howard Horn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,785
-1.65%
|
$71,400
$40.4 P/Share
|
|
Mar 03
2025
|
Thomas Richard Kassberg CBO & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
508
-0.19%
|
$21,336
$42.92 P/Share
|
|
Mar 03
2025
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
6,028
-2.22%
|
$253,176
$42.1 P/Share
|
|
Mar 03
2025
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,945
-11.06%
|
$375,690
$42.1 P/Share
|
|
Mar 03
2025
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
12,846
-14.58%
|
$539,532
$42.1 P/Share
|
|
Mar 03
2025
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
73,434
-10.27%
|
$3,084,228
$42.1 P/Share
|
|
Mar 03
2025
|
John Richard Pinion |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.03%
|
$1,302
$42.92 P/Share
|
|
Mar 03
2025
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
14,439
-11.82%
|
$606,438
$42.1 P/Share
|
|
Mar 03
2025
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,103
-14.67%
|
$634,326
$42.1 P/Share
|
|
Mar 03
2025
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-0.28%
|
$5,922
$42.92 P/Share
|
|
Mar 03
2025
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
967
-1.89%
|
$40,614
$42.1 P/Share
|
|
Mar 03
2025
|
Dennis Karl Huang |
SELL
Payment of exercise price or tax liability
|
Direct |
1,348
-1.16%
|
$56,616
$42.92 P/Share
|
|
Mar 01
2025
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
18,443
+6.37%
|
-
|
|
Mar 01
2025
|
Eric Crombez EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,784
+18.11%
|
-
|
|
Mar 01
2025
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,937
+17.26%
|
-
|
|
Mar 01
2025
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,560
+9.85%
|
-
|
|
Mar 01
2025
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
32,937
+12.68%
|
-
|
|
Mar 01
2025
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,256
+15.97%
|
-
|
|
Mar 01
2025
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,392
+15.49%
|
-
|
|
Mar 01
2025
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
32,937
+13.33%
|
-
|
|
Mar 01
2025
|
Howard Horn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,653
+12.66%
|
-
|
|
Feb 28
2025
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
25,000
-1.14%
|
$1,050,000
$42.48 P/Share
|
|
Feb 27
2025
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,990
-2.6%
|
$125,580
$42.84 P/Share
|